Potential efficacy of immunosuppressant in the treatment of COVID-19
10.3760/cma.j.cn112309-20200408-00180
- VernacularTitle:免疫抑制剂在COVID-19患者中的潜在应用价值
- Author:
Wenbin SONG
1
;
Xingde LI
;
Jinying BAO
;
Yang ZHANG
;
Cangsang SONG
Author Information
1. 昆明市第一人民医院，昆明医科大学附属甘美医院药学部 650051
- From:
Chinese Journal of Microbiology and Immunology
2020;40(7):505-510
- CountryChina
- Language:Chinese
-
Abstract:
The outbreak of COVID-19 has infected millions of people and caused hundreds of thousands of deaths worldwide. As there is no specific medicines or effective vaccines against 2019-nCoV at present, it is an alternative strategy to repurpose existing drugs for new diseases. Cyclosporin A inhibits the replication of coronaviruses by binding to cellular cyclophilins. Chloroquine/hydroxychloroquine can block virus-receptor binding through interfering with terminal glycosylation of the cellular receptor angiotensin-converting enzyme 2 (ACE2). Trastuzumab prevents the binding of IL-6 to both sIL-6R and mIL-6R and thereby inhibits the cytokine storm syndrome induced by COVID-19. This paper discussed the potential anti-2019-nCoV effects of some common immunosuppressant including cyclosporine, chloroquine/hydroxychloroquine, and tocilizumab.
